Step-by-Step Guide to the CDSCO Clinical Trial Approval Process in India

The Central Drugs Standard Control Organization (CDSCO) is India’s national regulatory authority responsible for approving and overseeing clinical trials under the New Drugs and Clinical Trials (NDCT) Rules, 2019. Whether for new drugs, investigational products, biologics, or bioequivalence (BA/BE) studies, CDSCO approval is mandatory prior to trial initiation. This article provides a structured, step-by-step guide for obtaining clinical trial approval from CDSCO, including key documents, timelines, forms, and compliance requirements.

Legal and Regulatory Framework:

• NDCT Rules, 2019 (in force since March 19, 2019)
• Drugs and Cosmetics Act, 1940 (as applicable)
• CDSCO Guidance Documents and GSR Notifications

When is CDSCO Approval Required?

CDSCO approval is mandatory for the following clinical trial types in India:

• New Chemical Entities (NCEs)
• Investigational New Drugs (INDs)
• Biologicals including vaccines and biosimilars
• Global clinical trials (GCTs)
• BA/BE studies in healthy volunteers
• Medical devices (Class C & D)

Stakeholders Involved in Approval Process:

1. Sponsor: Indian or global company initiating the trial
2. Authorized Clinical Research Organization (CRO): Executes the trial and files submissions
3. Ethics Committee (EC): Reviews and approves the trial protocol locally
4. Principal Investigator (PI): Leads the study at trial sites
5. Drugs Controller General of India (DCGI): Grants trial approval on behalf of CDSCO

Step-by-Step CDSCO Approval Process:

1. Step 1: Pre-Submission Planning
   • Identify trial classification: new drug, global study, BA/BE, or post-marketing
   • Ensure Ethics Committee registration is valid and active
   • Finalize study protocol and Informed Consent Documents (ICDs)
2. Step 2: Online Registration on SUGAM Portal
   • Register sponsor/CRO account at SUGAM portal
   • Provide firm details, DSC (digital signature certificate), and upload registration documents
3. Step 3: Submission of Form CT-04
   • Form CT-04 is used to apply for permission to conduct a clinical trial
   • Include protocol, IB, preclinical data, manufacturing details, EC approval letters, PI credentials, etc.
   • Pay government fees through Bharatkosh portal
4. Step 4: Review and Queries by CDSCO
   • CDSCO may raise queries within 30–60 working days
   • Sponsor must respond with clarification, additional data, or revised documents
5. Step 5: Grant of Permission – Form CT-06
   • CDSCO issues approval via Form CT-06 allowing trial initiation
   • Valid for 2 years and includes conditions for reporting and conduct

Key Documents Required for Submission:

• Final Protocol and Synopsis
• Investigator’s Brochure
• Informed Consent Form (English + vernacular)
• Ethics Committee Approvals
• Drug Manufacturing License or Import License (Form CT-16)
• Preclinical toxicology and pharmacology reports
• Clinical trial insurance certificate
• Financial disclosure by investigators

Timelines for CDSCO Approval:

Post-Approval Obligations:

• Register trial on CTRI before enrollment
• Submit Serious Adverse Event (SAE) reports within 14 days
• Submit protocol amendments, deviations, and annual status reports
• Maintain trial master file (TMF) and ensure audit readiness

Common Pitfalls and How to Avoid Them:

• Incomplete Documentation: Use a compliance checklist from Pharma SOPs
• Delayed EC Approvals: Start EC submissions in parallel to SUGAM application
• Query Handling: Maintain a regulatory tracker for addressing CDSCO queries promptly

Integration with Global Clinical Development:

CDSCO approval aligns with international standards like ICH-GCP and frameworks from agencies such as the USFDA and EMA. Global studies can initiate India arms in parallel by aligning timelines, documentation, and protocol amendments across jurisdictions.

Conclusion:

Understanding the CDSCO clinical trial approval process is critical for pharmaceutical sponsors, CROs, and investigators conducting research in India. By following a structured submission approach, aligning documentation with NDCT rules, and ensuring timely responses to regulatory queries, applicants can expedite approvals and avoid trial delays. Platforms like Stability Studies help in trial readiness, regulatory planning, and documentation alignment throughout the approval journey.

CDSCO Import License for Clinical Trial Drugs in India: Step-by-Step Guide

Importing clinical trial drugs into India requires authorization from the Central Drugs Standard Control Organization (CDSCO) under the New Drugs and Clinical Trials (NDCT) Rules, 2019. Sponsors, CROs, or importers must apply for an import license to legally bring investigational products (IPs), new chemical entities (NCEs), biologics, or comparator drugs into the country for clinical research. This guide provides a comprehensive walkthrough of the CDSCO import licensing process for clinical trial drugs in India.

Regulatory Basis and Governing Law:

• NDCT Rules, 2019, Chapter VII – Manufacturing or Import of New Drugs for Clinical Trials
• GSR 227(E), March 19, 2019
• Form CT-16 and CT-17 (as per CDSCO requirements)
• Guidance on SUGAM portal submission and import regulations

When is an Import License Required?

• Import of investigational products for approved clinical trials
• Import of placebo or comparator drugs
• Import of reference standards, kits, or auxiliary materials used in the trial
• Import of modified dosage forms for BA/BE studies

Types of Applicants Eligible to Apply:

• Sponsor (Indian or multinational company)
• Contract Research Organization (CRO) authorized by sponsor
• Importer or distributor with valid drug licenses
• Authorized Indian legal representative (in case sponsor is foreign)

Key Forms and Documentation:

1. Form CT-16: Application form for import license
2. Form CT-17: License issued by CDSCO for approved import
3. Copy of Clinical Trial Approval Letter from CDSCO (Form CT-06)
4. Details of protocol, product label, and trial design
5. Free Sale Certificate (FSC) from the exporting country
6. Drug Master File (DMF) or equivalent technical dossier
7. Letter of Authorization from sponsor (if applicable)
8. Batch release certificate and Certificate of Analysis (CoA)
9. Storage and handling SOPs

Online Application Procedure via SUGAM Portal:

1. Visit the CDSCO website and log into the SUGAM portal.
2. Register as an Importer or Sponsor with complete organizational details.
3. Navigate to the “Import of Investigational Drugs” section.
4. Fill out Form CT-16 with drug, sponsor, clinical trial, and shipment information.
5. Upload supporting documents (PDF format, digitally signed).
6. Pay applicable government fees through Bharatkosh portal and upload receipt.
7. Submit the application and track status using reference number.

Processing Timeline and Review:

• CDSCO typically reviews the application within 30 working days.
• Queries, if any, are raised via the portal and must be addressed promptly.
• Upon approval, Form CT-17 is issued to the applicant for each drug and batch.

Import and Customs Clearance:

After obtaining Form CT-17, the sponsor/importer must submit the following to Indian customs:

• Copy of Form CT-17 and clinical trial approval
• Shipping invoice, air waybill, and packing list
• Batch-specific CoA and temperature logs (if applicable)
• Letter of Authorization to customs broker

Common Challenges and Mitigation:

• Challenge: Incomplete documentation or unclear labeling
• Solution: Use SOP checklists from Pharma SOPs for import readiness
• Challenge: Delay in payment verification or form upload errors
• Solution: Perform trial runs on the SUGAM portal before official submission
• Challenge: Customs clearance bottlenecks for temperature-sensitive drugs
• Solution: Coordinate with a GMP-compliant cold chain logistics provider and ensure GMP quality control in packaging

Compliance Obligations Post-Import:

• Maintain import register with batch details, expiry, and usage
• Submit utilization report to CDSCO post-trial
• Ensure trial site documentation for storage and dispensing is GCP-compliant
• Include imported drugs in trial master file (TMF)

Inspections and Enforcement:

CDSCO or Drug Inspectors may audit sponsor offices or trial sites for verifying import compliance, drug accountability, and storage conditions. Violations may result in import license suspension or clinical trial halt.

Integration with International Practices:

India’s regulatory requirements for investigational drug imports align with EMA and USFDA standards. However, the CDSCO process mandates local sponsor or importer accountability and SUGAM digital workflow adherence.

Conclusion:

Securing an import license from CDSCO is a critical compliance milestone for conducting clinical trials in India. Sponsors must carefully plan documentation, timelines, and logistics in alignment with NDCT rules. Leveraging regulatory platforms such as Stability Studies can further streamline import-readiness and ensure smooth execution of clinical trials with full regulatory compliance.